Jade Biosciences, Inc. (JBIO)

Jade Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024
Period Ending	Dec 31, 2024
Selling, General & Admin	8.61
Research & Development	55.87
Operating Expenses	64.48
Operating Income	-64.48
Interest & Investment Income	2.32
Other Non Operating Income (Expenses)	-25.2
EBT Excluding Unusual Items	-87.36
Other Unusual Items	-6.6
Pretax Income	-93.96
Net Income	-93.96
Net Income to Common	-93.96
Shares Outstanding (Basic)	5
Shares Outstanding (Diluted)	5
EPS (Basic)	-18.79
EPS (Diluted)	-18.79
EBIT	-64.48

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q